Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model

Mansi Shah, Parshotam Madan, Senshang Lin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Enhanced oral bioavailability of poorly aqueous soluble drugs encapsulated in solid lipid nanoparticles (SLNs) via lymphatic delivery has been documented. Since no in-vitro lymphoid tissue is currently available, human excised Caco-2 cell monolayer could be alternative tissue for development of an in-vitro model to be used as a screening tool before animal studies are undertaken. Therefore, optimized carvedilol-loaded SLNs (FOPT-SLNs) were prepared, characterized, and evaluated using Caco-2 cell line as an in-vitro model. Physical mixture of components of FOPT-SLNs (FOPT-PM) and carvedilol solution were used as control groups. From the studies of effect of SLNs concentration and cells incubation time, suitable carvedilol concentration and incubation time were selected for the model in which cells were subjected to five pretreatments for 24 h or 1 h of cell incubation and then followed with treatment of FOPT-SLNs, FOPT-PM or 100μg/mL solution of carvedilol, for additional 24 h of cell incubation. The results obtained in this model suggest that main absorption mechanism of FOPT-SLNs could be endocytosis and, more specifically, clathrin-mediated endocytosis. When Transwell® permeable supports were used for the cells, carrier-mediated mechanism for FOPT-SLNs and passive absorption mechanism (transcellular and paracellular) for FOPT-PM and drug solution were concluded.

Original languageEnglish (US)
Pages (from-to)877-885
Number of pages9
JournalPharmaceutical Development and Technology
Volume20
Issue number7
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Caco-2 Cells
Intestinal Absorption
Nanoparticles
Lipids
Cell Line
Endocytosis
Clathrin
In Vitro Techniques
carvedilol
Lymphoid Tissue
Pharmaceutical Preparations
Biological Availability
Control Groups

Keywords

  • Absorption mechanism
  • Caco-2 cells
  • Carvedilol
  • Cellular uptake
  • Intestinal absorption
  • Solid lipid nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model. / Shah, Mansi; Madan, Parshotam; Lin, Senshang.

In: Pharmaceutical Development and Technology, Vol. 20, No. 7, 01.01.2015, p. 877-885.

Research output: Contribution to journalArticle

@article{942c1b2325d94f4f8d7fff736502926f,
title = "Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model",
abstract = "Enhanced oral bioavailability of poorly aqueous soluble drugs encapsulated in solid lipid nanoparticles (SLNs) via lymphatic delivery has been documented. Since no in-vitro lymphoid tissue is currently available, human excised Caco-2 cell monolayer could be alternative tissue for development of an in-vitro model to be used as a screening tool before animal studies are undertaken. Therefore, optimized carvedilol-loaded SLNs (FOPT-SLNs) were prepared, characterized, and evaluated using Caco-2 cell line as an in-vitro model. Physical mixture of components of FOPT-SLNs (FOPT-PM) and carvedilol solution were used as control groups. From the studies of effect of SLNs concentration and cells incubation time, suitable carvedilol concentration and incubation time were selected for the model in which cells were subjected to five pretreatments for 24 h or 1 h of cell incubation and then followed with treatment of FOPT-SLNs, FOPT-PM or 100μg/mL solution of carvedilol, for additional 24 h of cell incubation. The results obtained in this model suggest that main absorption mechanism of FOPT-SLNs could be endocytosis and, more specifically, clathrin-mediated endocytosis. When Transwell{\circledR} permeable supports were used for the cells, carrier-mediated mechanism for FOPT-SLNs and passive absorption mechanism (transcellular and paracellular) for FOPT-PM and drug solution were concluded.",
keywords = "Absorption mechanism, Caco-2 cells, Carvedilol, Cellular uptake, Intestinal absorption, Solid lipid nanoparticles",
author = "Mansi Shah and Parshotam Madan and Senshang Lin",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/10837450.2014.938857",
language = "English (US)",
volume = "20",
pages = "877--885",
journal = "Pharmaceutical Development and Technology",
issn = "1083-7450",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model

AU - Shah, Mansi

AU - Madan, Parshotam

AU - Lin, Senshang

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Enhanced oral bioavailability of poorly aqueous soluble drugs encapsulated in solid lipid nanoparticles (SLNs) via lymphatic delivery has been documented. Since no in-vitro lymphoid tissue is currently available, human excised Caco-2 cell monolayer could be alternative tissue for development of an in-vitro model to be used as a screening tool before animal studies are undertaken. Therefore, optimized carvedilol-loaded SLNs (FOPT-SLNs) were prepared, characterized, and evaluated using Caco-2 cell line as an in-vitro model. Physical mixture of components of FOPT-SLNs (FOPT-PM) and carvedilol solution were used as control groups. From the studies of effect of SLNs concentration and cells incubation time, suitable carvedilol concentration and incubation time were selected for the model in which cells were subjected to five pretreatments for 24 h or 1 h of cell incubation and then followed with treatment of FOPT-SLNs, FOPT-PM or 100μg/mL solution of carvedilol, for additional 24 h of cell incubation. The results obtained in this model suggest that main absorption mechanism of FOPT-SLNs could be endocytosis and, more specifically, clathrin-mediated endocytosis. When Transwell® permeable supports were used for the cells, carrier-mediated mechanism for FOPT-SLNs and passive absorption mechanism (transcellular and paracellular) for FOPT-PM and drug solution were concluded.

AB - Enhanced oral bioavailability of poorly aqueous soluble drugs encapsulated in solid lipid nanoparticles (SLNs) via lymphatic delivery has been documented. Since no in-vitro lymphoid tissue is currently available, human excised Caco-2 cell monolayer could be alternative tissue for development of an in-vitro model to be used as a screening tool before animal studies are undertaken. Therefore, optimized carvedilol-loaded SLNs (FOPT-SLNs) were prepared, characterized, and evaluated using Caco-2 cell line as an in-vitro model. Physical mixture of components of FOPT-SLNs (FOPT-PM) and carvedilol solution were used as control groups. From the studies of effect of SLNs concentration and cells incubation time, suitable carvedilol concentration and incubation time were selected for the model in which cells were subjected to five pretreatments for 24 h or 1 h of cell incubation and then followed with treatment of FOPT-SLNs, FOPT-PM or 100μg/mL solution of carvedilol, for additional 24 h of cell incubation. The results obtained in this model suggest that main absorption mechanism of FOPT-SLNs could be endocytosis and, more specifically, clathrin-mediated endocytosis. When Transwell® permeable supports were used for the cells, carrier-mediated mechanism for FOPT-SLNs and passive absorption mechanism (transcellular and paracellular) for FOPT-PM and drug solution were concluded.

KW - Absorption mechanism

KW - Caco-2 cells

KW - Carvedilol

KW - Cellular uptake

KW - Intestinal absorption

KW - Solid lipid nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84964374749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964374749&partnerID=8YFLogxK

U2 - 10.3109/10837450.2014.938857

DO - 10.3109/10837450.2014.938857

M3 - Article

VL - 20

SP - 877

EP - 885

JO - Pharmaceutical Development and Technology

JF - Pharmaceutical Development and Technology

SN - 1083-7450

IS - 7

ER -